The Allergy Immunotherapy Market, estimated at USD 2,740.6 Mn in 2025, is expected to exhibit a CAGR of 9.8% and reach USD 5,276.5 Mn by 2032.
The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.
Market Dynamics:
Global allergy immunotherapy market growth is driven by rising prevalence of allergic diseases globally and growing adoption of sublingual immunotherapy. According to Asthma and Allergy Foundation of America, more than 50 million Americans suffer from allergies each year. Environmental factors such as air pollution and changing climate increases exposure to outdoor and indoor allergens. This has significantly contributed to growth of the number of people diagnosed with allergic rhinitis, asthma and other respiratory allergies. Furthermore, sublingual immunotherapy has gained immense popularity as a reliable alternative to conventional allergy shots in the recent years due to its efficacy and convenience. With advantages such as ease of administration and fewer side effects, sublingual tablets are widely preferred by both patients as well physicians for effective long-term treatment of respiratory allergies.
Growing prevalence of allergies is driving the market growth
Rising prevalence of allergic diseases like asthma, allergic rhinitis, and atopic dermatitis is expected to drive the market growth. According to research, more than 50 million Americans currently suffer from some form of allergy. This rise in allergic patient population boosts demand for allergy immunotherapy. Immunotherapy is considered the only disease-modifying treatment option for allergies that can potentially provide long-term relief or cure after years of treatment. Growing patient pool diagnosed with different types of allergies worldwide provides a large target population for immunotherapy manufacturers.
Increasing awareness about immunotherapy drives the market growth
There has been increasing awareness among both patients and physicians about the advantages of immunotherapy over conventional treatment options like medications. Consumers are more informed about how immunotherapy aims to induce tolerance to specific allergens and provide long lasting relief after a few years of treatment. Unlike medications, immunotherapy does not provide only symptomatic relief but can potentially cure allergies. This awareness about disease-modifying benefits can drive the market growth. Various educational campaigns by industry players and allergist associations have enhanced knowledge about proper usage and success rates of immunotherapy. This boosts demand for safe and effective allergy immunotherapy products.
High cost of immunotherapy can hamper the market growth
Despite the rising prevalence of allergies and benefits of immunotherapy, its high cost deters many patients and physicians from adopting it as the first line of treatment. The therapy requires years of maintenance doses, which increases the overall cost. For example, the entire cost of 3-5 years of sublingual immunotherapy treatment can range from US$ 2,000 to US$ 5,000, making it unaffordable for many people. Even the healthcare systems in developed nations do not always provide full coverage for the immunotherapy cost. This financial burden on patients poses a major challenge for the market growth in terms of accessibility and volume sales.